
# **Burundi ALMA Quarterly Report Quarter Four, 2022**



# **Scorecard for Accountability and Action**



Commodities Financed		
LLIN financing 2022 projection (% of need)		85
Public sector RDT financing 2022 projection (% of need)		100
Public sector ACT financing 2022 projection (% of need)		100
Policy		
Signed, ratified and deposited the AMA instrument at the AUC		
Malaria activities targeting refugees in Malaria Strategic Plan		
Malaria activities targeting IDPs in Malaria Strategic Plan		
Country Reporting Launch of Zero Malaria Starts with Me Campaign		
Resistance Monitoring, Implementation and Impact		
Drug Resistance Monitoring Conducted (2018-2020) and data reported to WHO		
Insecticide classes with mosquito resistance in representative sentinel sites confirmed since 2010		;
Insecticide resistance monitored since 2015 and data reported to WHO		
National Insecticide Resistance Monitoring and Management Plan		
RDTs in stock (>6 months stock)		
ACTs in stock (>6 months stock)	<b>A</b>	
LLIN/IRS campaign on track		
Operational LLIN/IRS coverage (% of at risk population)		100
On track to reduce case incidence by ≥40% by 2021 (vs 2015)		
On track to reduce case mortality by ≥40% by 2021 (vs 2015)		
Tracer Indicators for Maternal and Child Health, NTDs an	d C	ovid 19
Scale of Implementation of ICCM		
Mass Treatment Coverage for Neglected Tropical Disease (NTD index, %)(2021)	v	11
Estimated % of children (0–14 years old) living with HIV who have access to antiretroviral therapy (2021)		30
Vitamin A Coverage 2021 (2 doses)	•	8
DPT3 coverage 2021 (vaccination among 0-11 month olds)		94

In Burundi, about 24% of the population is at high risk for malaria and nearly 22% live in malaria-free highland areas. The annual reported number of malaria cases in 2021 was 6,618,492 with 2,292 deaths.

# Key



# **Burundi ALMA Quarterly Report Quarter Four, 2022**



### Malaria

## **Global Fund Update**

The Global Fund has announced that Burundi will receive US\$124.2 million for HIV, tuberculosis, malaria, and health systems strengthening as the country allocation for 2024-2026. The Global Fund has determined the total allocation amount based on Burundi's disease burden and income level, as well as several other factors. The malaria component is also allocated a specific proportion of the total, according to a formula developed by the Global Fund that takes into account several factors, including disease burden and the importance of sustaining life-saving essential services. For Burundi this is calculated at US\$76.1 million. The allocations to the individual disease components are not fixed, and can be adjusted according to decisions made at country level. Burundi is urged to ensure that resources are allocated to malaria control from the overall Global Fund country allocation, as well as from domestic resources, to accelerate progress.

#### **Progress**

The country continues to work on strengthening and maintaining health services following the devastating impact of the COVID-19 pandemic. In this regard Burundi procured sufficient LLINs to achieve universal coverage of the targeted at risk population. The country secured sufficient resources to procure the ACTs and RDTs required in 2022 and has good stocks of ACTs and RDTs. The country has carried out drug resistance monitoring since 2018, and insecticide resistance monitoring since 2015 and has reported the results to WHO. The country has also developed an insecticide resistance monitoring and management plan. The national strategic plan includes activities targeting refugees and IDPs.

In line with the priority agenda of the ALMA chair, His Excellency President Umaro Sissoco Embaló, Burundi has significantly enhanced the tracking and accountability mechanisms for malaria with the development of a Malaria Control Scorecard. This scorecard tool has been updated and is being decentralized but has not yet been shared on the ALMA Scorecard Hub. The country RMNCAH scorecard has been shared through the Scorecard Hub.

#### **Impact**

The annual reported number of malaria cases in 2021 was 6,618,492 with 2,292 deaths.

#### **Key Challenges**

- The country has experienced a malaria upsurge from 2015.
- Gaps to further scale up IRS.
- Sustaining the delivery of essential life-saving interventions during the COVID-19 pandemic including for Reproductive, Maternal, Newborn, Adolescent and Child health, malaria and Neglected Tropical Diseases.

**Previous Key Recommended Actions** 

Objective	Action Item	Suggested completion timeframe	Progress	Comments - key activities/accomplishments since last quarterly report
Impact	Ensure that malaria services including case management and vector control are sustained and implemented whilst using COVID-19 sensitive guidelines during the pandemic	Q4 2022		Malaria control and elimination activities are being conducted in Burundi whilst respecting COVID-19 preventive measure. The LLIN campaign was completed. Community Case Management has been expanded to the over fives. The IRS campaign was competed in Q4 2022. The country has sufficient stocks of ACTs and RDTs with a good supply pipeline
Impact	Work to address the low stocks of ACTs	Q1 2023		Urgent ACT and RDT deliveries were made, and now the stock status has significantly improved with more than 5 months of stock available

**New Key Recommended Action** 

Objective	Action Item	Suggested completion timeframe
Impact	Investigate and address the reasons for the increase in estimated malaria incidence a between 2015 and 2021	Q4 2023

## **RMNCAH and NTDs**

## **Progress**

Burundi has achieved high coverage of tracer RMNCAH interventions, including DPT3 and vitamin A coverage. Burundi enhanced the tracking and accountability mechanisms with the development of a Reproductive, Maternal, Newborn, Child and Adolescent Health Scorecard.

Progress in addressing Neglected Tropical Diseases (NTDs) in Burundi is measured using a composite index calculated from preventive chemotherapy coverage achieved for onchocerciasis, schistosomiasis, soil transmitted helminths and trachoma. Preventive chemotherapy coverage in Burundi is high for trachoma (100%), schistosomiasis (100%), soil-transmitted helminths (98%) and zero for onchocerciasis (0%). Overall, the NTD preventive chemotherapy coverage index for Burundi in 2021 is 18 and this represents a very substantial decrease compared with the 2020 index value (95).


**Previous Key Recommended Actions** 

Objective	Action Item	Suggested completion timeframe	Progress	Comments - key activities/accomplishments since last quarterly report
RMNCAH¹: Impact	Ensure that essential RMNCAH services are sustained and implemented whilst using COVID-19 sensitive guidelines during the pandemic. Address any stock-outs of essential RMNCAH commodities	Q4 2022		The country is conducting RMNCAH activities as planned whilst respecting COVID-19 measures. In Q4 2022, in addition to routine activities, the country organized a dissemination workshop of national RMNCAH guidelines including the guidelines of self-pregnancy testing for the community in Muyinga, Cankuzo and Kirundo provinces. Community leaders were also sensitized on the importance of cervical cancer screening and treatment. Other activities include the training of 40 health workers in charge of maternal and perinatal deaths surveillance in Rutana province
NTDs	Ensure that NTD interventions are sustained and implemented whilst using COVID-19 sensitive guidelines during the pandemic. This includes prioritising key necessary catchup activities	Q4 2021		Burundi is conducting NTD prevention and control interventions whilst respecting COVID-19 safety measures. In Q4 2022, the country worked on the Trachoma elimination dossier and on the new NTD Master Plan 2023-2027. The country is also in the preparations of the mapping of onchocerciasis elimination

Burundi has responded positively to the RMNCAH recommended actions addressing low coverage of ART coverage in children, with a 2% increase in coverage reported in the last year.

**New Key Recommended Actions** 

Objective	Action Item	Suggested completion timeframe
Optimise quality of care	Address the falling coverage of vitamin A	Q4 2023
NTDs	Work to implement preventive chemotherapy for onchocerciasis and reach WHO targets	Q4 2023



<sup>&</sup>lt;sup>1</sup> RMNCAH metrics, recommended actions and response tracked through WHO